How do I know if I'm eligible for targeted therapy?

Targeted & Hormone Therapy in Istanbul

In short

Targeted therapy uses drugs designed to act on a specific molecule driving a particular tumor's growth — like HER2, EGFR, or ALK — rather than affecting rapidly dividing cells generally the way chemotherapy does; hormone therapy, a related approach, blocks the hormones that fuel certain breast and prostate cancers. Both require biomarker or hormone-receptor testing first, since eligibility depends entirely on the tumor actually having the target. HER2+ targeted therapy in Istanbul runs $2,400–4,900 per cycle as an illustrative placeholder — about 63% less than Germany; other targeted regimens (EGFR/ALK inhibitors, etc.) are itemized per protocol in your personal quote, since they involve different drugs entirely.

Drugs act on a specific molecule (HER2, EGFR, ALK) driving your tumor, or block hormones fueling it. Requires biomarker testing first. HER2+ therapy in Istanbul runs $2,400–4,900/cycle (illustrative placeholder) — about 63% less than Germany.

Cost per cycle

UPDATED Q3 2026PLACEHOLDER

Component

Istanbul

Germany typ.

Typical use

HER2+ targeted therapy, administration

$2,400–4,900

$9,800

per cycle, trastuzumab-based

Includes administration, cardiac monitoring (ECHO scheduling), oncologist review; drug cost varies by originator vs. biosimilar and is always itemized separately. This is the one targeted-therapy price row currently published — other targeted regimens (EGFR/ALK inhibitors and others) involve different drugs entirely and are itemized per protocol in your personal quote.

Get an exact quote for your case

Cost per cycle

Q3 2026

HER2+ administration

$2,400–4,900

Germany typ. $9,800 · placeholder

How it's given

[ [ outpatient infusion suite ] ]

[ [ infusion suite ] ]

Outpatient infusion or oral therapy

Form

IV infusion (many targeted drugs) or daily oral pill

Setting

outpatient, for infusion-based regimens

Biomarker testing

required before starting — confirms the target is present

Interval

protocol-dependent — weekly to every 3 weeks for most infusions

Hormone therapy (for hormone-receptor-positive breast cancer, or androgen-deprivation therapy for prostate cancer) is usually a daily oral or periodic injectable regimen, distinct from the infusion-based targeted drugs above.

When it's typically used

Typically suitable

Tumors testing positive for the relevant biomarker (HER2, EGFR, ALK, hormone receptors, and others)

Often combined with or sequenced alongside chemotherapy or surgery

Hormone-receptor-positive breast cancer or prostate cancer, for hormone therapy specifically

Usually better served otherwise

Tumors that test negative for the relevant biomarker — the specific drug simply won't work

Cases where chemotherapy or immunotherapy is the better-indicated systemic option

Biomarker testing is what determines eligibility, not preference — the tumor board reviews your results and says so either way.

Typically suitable

Biomarker-positive tumors (HER2, EGFR, ALK, hormone receptors) · often combined with chemotherapy/surgery · hormone-receptor-positive cancers

Usually better served otherwise

Biomarker-negative tumors · cases better suited to chemotherapy or immunotherapy

Send your reports. Get a plan — with reasons.

A named specialist's board answers in 72 hours, free.

Free second opinionGet my free second opinion

Fair questions about targeted & hormone therapy

Your tumor tissue (or sometimes blood) is tested for the relevant biomarker — HER2, EGFR, ALK, or hormone receptors, depending on your cancer type. Only tumors that test positive for a given target respond to the matching drug.

Every cancer case is individual. Assessments do not replace in-person examination.Every cancer case is individual. Assessments are based on the reports you provide and do not replace in-person examination. Survival statistics are population-level data, not personal predictions.

Chemotherapy Immunotherapy EGFR mutation Lung cancer systemic therapy

Terms in this treatment

EGFR mutation →ALK rearrangement →

Verify at

Targeted Therapy for Cancer — National Cancer Institute (NCI)

Targeted therapies for cancer — MedlinePlus (U.S. National Library of Medicine)

Get my free second opinion